Vincent S LoPriore bought $500K of Hepion Pharmaceuticals (HEPA)
Executed Aug 3, disclosed Aug 13, 9 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Aug 12), the stock returned +47.1% (delay-adjusted); from the execution session (Aug 3), +56.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Vincent S LoPriore (Executive Chairman) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales, 2 filed past the two-business-day deadline), most often in Hepion Pharmaceuticals, Inc. (HEPA). Across 2 priced purchase filings, the average 21-session return was +64.1% from execution and +27.9% from disclosure (delay-adjusted; derived). The largest single filing was $500K of HEPA (10,000,000 sh across 2 lots, as filed), executed Aug 3.
Healthcare · Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), meta…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→5,000,000 sh × $0.04
Exec Apr 21
Filed Apr 27 · 6:24 AM ET †